Fogpharma Announces $178 Million Series D Financing To Advance Pipeline Of First-In-Class Helicon Polypeptide Therapeutics Targeting Major Cancer Drivers
Fogpharma Announces $178 Million Series D Financing To Advance Pipeline Of First-In-Class Helicon Polypeptide Therapeutics Targeting Major Cancer Drivers
11/21/22, 1:32 PM
Location
cambridgeMoney raised
$178 million
Industry
biotechnology
health care
therapeutics
pharmaceutical
Round Type
series d
Investors
Casdin Capital, Hbm Healthcare Investments, Farallon Capital Management, Gv, Cormorant Asset Management, Deerfield Management, Ven Bio Partners, Fidelity Management & Research Company, Milky Way Investments, Arch Venture Partners
FogPharma®, a biopharmaceutical company pioneering a new class of precision medicines that could ultimately prove applicable to the vast majority of therapeutic targets, including those previously considered “undruggable,” today announced a $178 Million Series D financing. The financing round includes new investors ARCH Venture Partners, Milky Way Investments and Fidelity Management & Research Company and existing investors VenBio Partners, Deerfield Management, GV, Cormorant Asset Management, funds and accounts advised by T. Rowe Price Associates, Inc., Invus, Farallon Capital Management, HBM Healthcare Investments, Casdin Capital, and PagsGroup, also participated.
Company Info
Location
30 acorn park drive
cambridge, massachusetts, united states
Additional Info
FogPharma is developing a new class of drugs to address the limitations of today’s precision medicines and achieve universal druggability. The company is pioneering the discovery, development and commercialization of HeliconTM peptides, a new drug modality that uniquely combines the broad targeting power of monoclonal antibodies with the cell-penetrating ability of small molecules. HeliconTM peptides hold the promise, not only to drug nearly all human disease drivers, but also to do so with unrivaled speed and scalability.